Interferon-α in Oncology Patients: Fewer Psychiatric Side Effects Than Anticipated

2008 ◽  
Vol 49 (1) ◽  
pp. 56-63 ◽  
Author(s):  
Marjolein Bannink ◽  
Wim H.J. Kruit ◽  
Arthur R. Van Gool ◽  
Stefan Sleijfer ◽  
Bronno van der Holt ◽  
...  
Keyword(s):  
Side Effects ◽  
Interferon Α ◽  
Oncology Patients ◽  
Psychiatric Side Effects

Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects

2007 ◽  
Vol 55 (3-4) ◽  
pp. 225-231 ◽  
Author(s):  
Marjolein Bannink ◽  
Durk Fekkes ◽  
Arthur R. Van Gool ◽  
Wim H.J. Kruit ◽  
Stefan Sleijfer ◽  
...  
Keyword(s):  
Side Effects ◽  
Tryptophan Metabolism ◽  
Interferon Α ◽  
Psychiatric Side Effects

Celecoxib, ibuprofen, and indomethacin alleviate depression-like behavior induced by interferon-alfa in mice

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Azadeh Mesripour ◽  
Shahrzad Shahnooshi ◽  
Valiollah Hajhashemi
Keyword(s):  
Side Effects ◽  
Forced Swimming Test ◽  
Interferon Alfa ◽  
Interferon Α ◽  
High Dose ◽  
Antidepressant Effects ◽  
Immobility Time ◽  
Inflammatory Drugs ◽  
Swimming Test ◽  
Psychiatric Side Effects

AbstractBackgroundInterferon-α (IFNα) therapy causes psychiatric side effects, including depression that may result in poor compliance of therapy. It is important to find alternative therapies for the prevention of IFNα induced depression. Non-steroidal anti-inflammatory drugs (NSAIDs) have been useful in depressive disorder. Therefore the effects of celecoxib, ibuprofen, and indomethacin were evaluated following IFNα-induced depression in mice.MethodsMale albino mice weighing 26 ± 2 g were used. Depression was induced by IFNα (16 × 105 IU/kg, SC) for six consecutive days. Animals were first subject to the locomotor test, then the splash test and finally the forced swimming test (FST) on the 7th day. The NSAIDs were administered (IP) either one single dose before the test, or simultaneously with IFNα.Resultslocomotor activity was only impaired by ibuprofen high dose (75 mg/kg), thus it was not further evaluated. Following IFNα therapy depression-like behaviors were observed; significant changes during the splash test (grooming time 24 ± 7 sec vs. control 63 ± 7 sec), the FST (immobility time 166  ± 15 sec vs. control 128  ± 6 sec), and sucrose preference reduced to 64 ± 0.8%. The NSAIDs noticeably reduced the immobility time in FST, while grooming time was increased. Celecoxib and indomethacin single doses were effective while ibuprofen showed better antidepressant effects when it was administered along with IFNα.ConclusionsThe NSAIDs were able to prevent IFNα induced depression in mice. NSAIDs administration with IFNα does not interfere with clinical benefit effects of IFNα and they could also be useful to prevent IFNα psychiatric side effects, thus further clinical trials are suggested.

Burns in a suicide attempt related to psychiatric side effects of interferon

Burns ◽  
1998 ◽  
Vol 24 (6) ◽  
pp. 581-583 ◽  
Author(s):  
K. Fukunishi ◽  
H. Tanaka ◽  
J. Maruyama ◽  
H. Takahashi ◽  
H. Kitagishi ◽  
...  
Keyword(s):  
Side Effects ◽  
Suicide Attempt ◽  
Psychiatric Side Effects

Receptiveness and barriers to clinical trial participation for oncology patients from a public safety-net hospital.

2021 ◽  
Vol 39 (28_suppl) ◽  
pp. 83-83
Author(s):  
Victor Yundeh Chiu ◽  
Jacob S. Berkowitz ◽  
Joshua Rodriguez ◽  
Jade Law ◽  
Kristina Lee ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Side Effects ◽  
Public Safety ◽  
Safety Net ◽  
Trial Participation ◽  
Religious Leader ◽  
Annual Income ◽  
Oncology Patients ◽  
Wage Loss ◽  
Safety Net Hospital

83 Background: Oncologic clinical trial enrollment is low, particularly in underserved populations. Increasing enrollment of public safety-net hospital patients is important to ensure representation of the general population and reduces cancer outcome disparities. To tailor clinical trial outreach, we sought to characterize attitudes towards trial participation of oncology patients at Olive View—UCLA Medical Center (OVMC), a public safety-net hospital in Los Angeles County. Methods: We developed a 39-question survey (Qualtrics, Provo, UT). It was administered via tablets to a convenience sample of patients in OVMC’s medical oncology clinic and infusion center during 2020—2021. The survey was offered to patients fluent in English or Spanish. Results: Of 165 patients who were offered the survey, 11 declined due to illiteracy in any language, 4 did not finish the survey. Median age was 54 (range: 20-81); 63% were female. The majority (76%) reported an annual income below $25,000; 39% did not complete high school. Self-identified ethnicity was Hispanic/Latino (73%), non-Hispanic White (12%), Asian-Pacific Islander (9%), and Black (4%). Based on a 5-point Likert scale of comfort speaking English, 48% had English proficiency (EP). Overall, 69% of patients expressed interest in trials. When considering participation, patients would seek advice from their physician (86%), family (32%), other medical staff (14%), alternative medicine practitioner (7%), friend (6%), or religious leader (4%). Concerns regarding trial participation were lack of knowledge regarding trials (47%), fear of side effects (43%), frequent visits (25%), cost (20%), transportation (14%), wage loss (9%), and inability to determine own treatment (4%). Patients found the following modalities useful for learning about trials: website (43%), paper handout (39%), video (37%), discussion with prior participants (34%). Patients with annual income > $25,000 were significantly more concerned about cost (33.3% v. 15.8%, p = 0.04) and treatment side effects (61.1% v. 36.8%, p = 0.02). EP patients were more likely to find a website (54.2% vs. 32.1%, p = 0.01) or discussion with prior participants (45.8% v. 23.1%, p < 0.01) helpful compared to low EP patients. Conclusions: There is considerable interest in oncologic clinical trials in this predominantly Hispanic/Latino population. This population had significant trust in physicians for guidance on trial enrollment, and had minimal concern for out-of-pocket cost, wage loss, or transportation issues. The majority of patients did not find additional informational resources helpful. Structural barriers rather than patient-level variables are likely the primary drivers of low oncologic trial enrollment. Future efforts should focus on improving access to appropriate trials and leveraging the physician-patient relationship for increasing trial participation.

P41 Psychiatric side effects of bilateral deep brain stimulation for movement disorders

Basal Ganglia ◽  
2011 ◽  
Vol 1 (2) ◽  
pp. 120-121
Author(s):  
M.O. Pinsker ◽  
F. Amtage ◽  
M. Berger ◽  
G. Nikkhah ◽  
L. Tebartz van Elst
Keyword(s):  
Deep Brain Stimulation ◽  
Side Effects ◽  
Brain Stimulation ◽  
Movement Disorders ◽  
Psychiatric Side Effects ◽  
Deep Brain
Sign in / Sign up

Export Citation Format

Share Document